ArticleBMC microbiology2025
ZAM-CS, a novel chimeric endolysin with enhanced stability and rapid action against methicillin-resistant Staphylococcus aureus.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Construction and Characterization of the Novel Engineered Endolysin ALC005: A New Alternative Antimicrobial AgainstMicroorganisms · 2026Article
- Combined experimental and in silico elucidation of KP27 endolysin reveals a phage derived antibacterial with pH and thermal robustness.Scientific reports · 2025Article
- Engineering a Potent Anti-MRSA Agent: The Development and Characterization of Chimeric Endolysin ZAM-MSC.Iranian biomedical journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe rising occurrence of antibiotic resistance in Staphylococcus aureus significantly complicates its treatment. Endolysins are now recognized as a promising substitute for antibiotics in combating multidrug-resistant bacteria. In this research, a novel chimeric endolysin named ZAM-CS was engineered and assessed to achieve enhanced stability, solubility, and rapid bactericidal activity. This was accomplished by combining the catalytic domain of the SAL-1 endolysin with the peptidoglycan binding domain of lysostaphin.
resultsExpression and purification outcomes indicated that ZAM-CS exhibited significant solubility, with a yield of approximately 23 mg/L. ZAM-CS demonstrated high stability under various temperature conditions and retained most of its activity in both acidic and alkaline pH. The results of turbidity reduction assay showed a 50% decrease in the initial OD600 within 10 min at a minimum concentration of 2 µg/mL. The minimum inhibitory concentration and the minimum bactericidal concentration values of ZAM-CS are identical in the methicillin-resistant Staphylococcus aureus strain, indicating the strong bactericidal properties of this endolysin. Antimicrobial tests showed ZAM-CS was also effective against coagulase-negative Staphylococci, Streptococcus agalactiae, and Enterococcus faecalis.
conclusionThe rapid and dynamic action and high stability of ZAM-CS compared to other recombinant endolysins make it a suitable candidate for development to replace antibiotics targeting harmful Staphylococci, including MRSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.